This page is intended for healthcare professionals in [COUNTRY] only
PONVORY® is indicated for the treatment of adult patients with RMS with active disease defined by clinical or imaging features[2]
PONVORY® is the first oral DMT that proved superiority in reducing relapses and lesions against an active oral comparator, teriflunomide, in a large Phase III study[2][3]
Discover the key clinical outcomes from the pivotal Phase III study and download a summary.
Gain insight on how PONVORY® offers convenience and flexibility that can be integral to treatment.
Access prescribing resources to help you prescribe PONVORY® with confidence.
Join the growing number of healthcare professionals that benefit from a wide range of online services:
Information on PONVORY® to support RMS patient care
Access to useful medical and scientific resources
The latest scientific data and treatment developments in PONVORY®
Discover how PONVORY® could meet the needs of newly-diagnosed patients with RMS
Discover how PONVORY® could meet the needs of newly-diagnosed patients with RMS
DMT=disease-modifying therapy
